JPMorgan Chase & Co. Sells 4,218 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

JPMorgan Chase & Co. cut its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 0.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 502,816 shares of the biotechnology company’s stock after selling 4,218 shares during the period. JPMorgan Chase & Co. owned 0.35% of Aurinia Pharmaceuticals worth $3,686,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of AUPH. Rhumbline Advisers boosted its holdings in Aurinia Pharmaceuticals by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 208,263 shares of the biotechnology company’s stock valued at $1,189,000 after purchasing an additional 24,371 shares during the period. AQR Capital Management LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter valued at $1,155,000. The Manufacturers Life Insurance Company boosted its stake in Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 4,808 shares during the period. Algert Global LLC grew its position in Aurinia Pharmaceuticals by 106.8% during the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock worth $1,107,000 after buying an additional 100,104 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in Aurinia Pharmaceuticals in the 2nd quarter worth about $84,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.30% of the stock is owned by insiders.

Aurinia Pharmaceuticals Trading Up 3.5 %

NASDAQ AUPH opened at $8.01 on Friday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock’s 50-day simple moving average is $8.75 and its two-hundred day simple moving average is $7.31. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -53.40 and a beta of 1.24.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.